Abstract
The introduction of stem cells in cardiology provides new tools in understanding the regenerative processes of the normal and pathologic heart and opens new options for the treatment of cardiovascular diseases. The feasibility of adult bone marrow autologous and allogenic cell therapy of ischemic cardiomyopathies has been demonstrated in humans. However, many unresolved questions remain to link experimental with clinical observations. The demonstration that the heart is a self-renewing organ and that its cell turnover is regulated by myocardial progenitor cells offers novel pathogenetic mechanisms underlying cardiac diseases and raises the possibility to regenerate the damaged heart. Indeed, cardiac stem progenitor cells (CSPCs) have recently been isolated from the human heart by several laboratories although differences in methodology and phenotypic profile have been described. The present review points to the potential role of CSPCs in the onset and development of congestive heart failure and its reversal by regenerative approaches aimed at the preservation and expansion of the resident pool of progenitors.
Keywords: Stem cells, myocardial regeneration, cardiovascular diseases, cardiac stem progenitor cells (CSPCs), cardiogenesis, cell migration, cardiomyocytes, smooth muscle cells, endothelial cells, gene expression
Current Pharmaceutical Design
Title: Resident Cardiac Stem Cells
Volume: 17 Issue: 30
Author(s): Stilli D., Quaini F., Quaini E., Anversa P., Kajstura J., Leri A., Urbanek K., Rossi F., De Angelis A., Falco A., Rossini A., Frati C., Musso E., Madeddu D., Ferraro F., Mangiaracina C., Rossetti P., Prezioso L., Cavalli S., Lagrasta C., Graiani G. and Savi M.
Affiliation:
Keywords: Stem cells, myocardial regeneration, cardiovascular diseases, cardiac stem progenitor cells (CSPCs), cardiogenesis, cell migration, cardiomyocytes, smooth muscle cells, endothelial cells, gene expression
Abstract: The introduction of stem cells in cardiology provides new tools in understanding the regenerative processes of the normal and pathologic heart and opens new options for the treatment of cardiovascular diseases. The feasibility of adult bone marrow autologous and allogenic cell therapy of ischemic cardiomyopathies has been demonstrated in humans. However, many unresolved questions remain to link experimental with clinical observations. The demonstration that the heart is a self-renewing organ and that its cell turnover is regulated by myocardial progenitor cells offers novel pathogenetic mechanisms underlying cardiac diseases and raises the possibility to regenerate the damaged heart. Indeed, cardiac stem progenitor cells (CSPCs) have recently been isolated from the human heart by several laboratories although differences in methodology and phenotypic profile have been described. The present review points to the potential role of CSPCs in the onset and development of congestive heart failure and its reversal by regenerative approaches aimed at the preservation and expansion of the resident pool of progenitors.
Export Options
About this article
Cite this article as:
D. Stilli, F. Quaini, E. Quaini, P. Anversa, J. Kajstura, A. Leri, K. Urbanek, F. Rossi, Angelis A. De, A. Falco, A. Rossini, C. Frati, E. Musso, D. Madeddu, F. Ferraro, C. Mangiaracina, P. Rossetti, L. Prezioso, S. Cavalli, C. Lagrasta, G. Graiani and M. Savi, Resident Cardiac Stem Cells, Current Pharmaceutical Design 2011; 17 (30) . https://dx.doi.org/10.2174/138161211797904181
DOI https://dx.doi.org/10.2174/138161211797904181 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Cardioprotective Effects of the I<sub>f</sub> Current Inhibition by Ivabradine During Cardiac Dysfunction
Current Pharmaceutical Biotechnology Donor-transmitted Anterior Myocardial Ischaemia in a Teenager: How to Proceed?
New Emirates Medical Journal A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, its Potential Benefit in Angina and Other Cardiovascular Disorders
Recent Patents on Cardiovascular Drug Discovery Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Sildenafil and Cardioprotection
Current Pharmaceutical Design Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews